SecBot SecBot

SION drug pipeline

Sionna Therapeutics, Inc. · 3 rated drugs
$3.33
−2.9% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2a (scheduled to initiate Q1 2027); Phase 1 completed
Time to marketAt least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.

SION-2222 galicaftor Updated Nov 10

What to watch

The next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.

Bull case
  • SION-2222 (galicaftor) is a TMD1-directed CFTR corrector that, combined with the NBD1 stabilizer SION-451, showed a well-tolerated safety profile in Phase 1 healthy volunteer dosing; in the SION-451 + SION-2222 cohorts most treatment-emergent adverse events were mild to moderate and no serious adverse events were reported.
  • The company has $249.8M in cash and securities as of Q3 2026, funding operations into H2 2029 and removing near-term dilution risk while the dual combination advances.
  • Sionna cut 46% of its workforce in September 2026 to focus exclusively on the SION-451 + SION-2222 dual combination, concentrating all resources on this single program.
Bear case
  • SION-2222 has never been tested in CF patients; the Phase 1 trial was only in healthy volunteers, so efficacy is entirely unproven.
  • The company's prior lead candidate SION-719 failed its Phase 2a endpoint in August 2026, eroding confidence in the NBD1 stabilizer platform and raising questions about whether SION-451 (the partner drug) will work.
  • Vertex Pharmaceuticals (VRTX) dominates the CF market with Trikafta, and Sionna's dual combination would need to show a compelling efficacy and safety profile to compete or carve out a niche.
◆ mixed
Impact
PhasePhase 1 completed; Phase 2a planned
Time to marketAt least 4-6 years away, if successful. The AscenSION CF Phase 2a trial has not yet started (expected Q1 2027). Even in a best case, Phase 2a readout would be 12-18 months away, followed by larger Phase 3 trials and FDA review.

SION-451 Updated Nov 10

What to watch

Watch for the initiation of the AscenSION CF Phase 2a trial for SION-451 + SION-2222 in Q1 2027. This trial start will signal the company's ability to execute after the workforce reduction, but the real binary event will be the Phase 2a topline efficacy readout, which is likely 12-18 months away. The stock's extreme post-failure valuation ($3.57, down 92% from the high) and $249M cash position create an asymmetric risk/reward, but SION-451 has no clinical proof-of-concept yet in patients.

Bull case
  • SION-451 targets a novel mechanism (NBD1 stabilization) that could address the root cause of CFTR dysfunction, potentially offering benefit to a broader CF population than current therapies. The company has a strong cash position of approximately $249 million, funding operations into 2029, which provides a long runway to generate clinical data. Analyst price targets show a mean of $21 (488% implied upside from the $3.57 close), with 6 Buy/Strong Buy ratings versus 11 Hold and 0 Sell. Several institutional investors added or doubled positions in Q2 and Q3 2026, including Adage Capital, Goldman Sachs, and Millennium Management.
Bear case
  • The company's lead program SION-719 failed its Phase 2a trial in August 2026, causing the stock to crash approximately 92% from its 52-week high of $54.97 to near $3.57. SION-451 has not yet demonstrated proof-of-concept in patients with CF; all Phase 1 data came from healthy volunteers. The company cut 46% of its workforce in September 2026, signaling significant organizational distress. Multiple analysts downgraded the stock after the August data, including Guggenheim (Buy to Neutral), Wedbush (Outperform to Neutral), and BTIG (Buy to Neutral). Major insider RA Capital Management sold over $21 million worth of shares on September 17, 2026. The AscenSION CF Phase 2a trial has not even started enrollment yet, and topline data is likely 12-18 months away.
▼ bearish
Impact
PhasePhase 2a (discontinued after failure)
Time to marketSION-719 has been discontinued and will not reach the market. The company's remaining pipeline candidate (SION-451 + SION-2222) is expected to enter Phase 2a in Q1 2027, with potential approval years away if successful.

SION-719 Updated Nov 10

What to watch

SION-719 has been discontinued after failing its Phase 2a endpoint. The next catalyst for Sionna is the AscenSION CF Phase 2a trial of SION-451 + SION-2222, expected to initiate in Q1 2027. Q3 2026 earnings were just reported on Nov 10, 2026, showing $249.8M cash and a $32.4M quarterly loss. Multiple securities fraud investigations are ongoing.

Bull case
  • Sionna ended Q3 2026 with $249.8M in cash, providing runway into 2029 to fund the pivot to SION-451 + SION-2222.
  • Post hoc analyses of the PreciSION CF data presented at NACFC 2026 reportedly support advancing SION-451 + SION-2222, suggesting the NBD1 stabilization mechanism may still have promise in a different combination format.
  • The stock at ~$3.74 is near its 52-week low of $3.19, and the mean analyst price target of $21 implies substantial upside if the remaining pipeline succeeds.
Bear case
  • SION-719 failed its Phase 2a PreciSION CF trial on the primary endpoint (sweat chloride reduction, p=0.7), and the program has been discontinued.
  • The stock crashed approximately 92% on August 10, 2026, when the failure was announced, erasing billions in market value.
  • Multiple law firms (Levi & Korsinsky, Robbins Geller, Pomerantz, Howard G. Smith) have launched securities fraud investigations into whether the company misled investors about SION-719's prospects.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
SION-719Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaPhase 2Completed15Jun 25, 2026